Skip to content
type1.science
Phase 1/2Active, not recruitingNCT00160732

Allogenic islet cell transplantation at University of Chicago

What this study tests

Per the registry (NCT00160732), a University of Chicago phase 1/2 allogeneic islet-cell protocol using intraportal infusion plus immunosuppression, listed as active but not recruiting; the registry describes a safety study in brittle/complex type 1 diabetes started in 2003.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2025-12-08.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Ages 18–58 with T1D for at least 5 years, undetectable C-peptide and metabolic instability, impaired hypoglycemia awareness or progressive complications despite intensive treatment. Transplantation and immunosuppression safety criteria apply. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • decrease in insulin requirement - Subjects able to maintain fasting blood glucose concentrations below 126 mg/dL and 2-hour post prandial levels below 180 mg/dL will be considered to be insulin independent.
  • decrease in incidence of hypoglycemic events

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]